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Available online 2 February 2018Background: Neuropathological ﬁndings support an autoimmune etiology as an underlying factor for loss of
orexin-producing neurons in spontaneous narcolepsy type 1 (narcolepsy with cataplexy; sNT1) as well as in
Pandemrix inﬂuenza vaccine-induced narcolepsy type 1 (Pdmx-NT1). The precise molecular target or antigens
for the immune response have, however, remained elusive.
Methods: Here we have performed a comprehensive antigenic repertoire analysis of sera using the next-
generation phage display method - mimotope variation analysis (MVA). Samples from 64 children and adoles-
cents were analyzed: 10 with Pdmx-NT1, 6 with sNT1, 16 Pandemrix-vaccinated, 16 H1N1 infected, and 16 un-
vaccinated healthy individuals. The diagnosis of NT1 was deﬁned by the American Academy of Sleep Medicine
international criteria of sleep disorders v3.
Findings:Our data showed that although the immunoproﬁles toward vaccination were generally similar in study
groups, there were also striking differences in immunoproﬁles between sNT1 and Pdmx-NT1 groups as com-
paredwith controls. Prominent immune responsewas observed to a peptide epitope derived from prostaglandin
D2 receptor (DP1), as well as peptides homologous to B cell lymphoma 6 protein. Further validation conﬁrmed
that these can act as true antigenic targets in discriminating NT1 diseased along with a novel epitope of hemag-
glutinin of H1N1 to delineate exposure to H1N1.
Interpretation:Wepropose that DP1 is a novelmolecular target of autoimmune response and presents a potential
diagnostic biomarker for NT1. DP1 is involved in the regulation of non-rapid eye movement (NREM) sleep and
thus alterations in its functions could contribute to the disturbed sleep regulation in NT1 that warrants further
studies. Together our results also show thatMVA is a helpfulmethod forﬁnding novel peptide antigens to classify
human autoimmune diseases, possibly facilitating the design of better therapies.
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Narcolepsy type 1
H1N1
Pandemrix
Antibody
Prostaglandin
DP11. Introduction
Narcolepsy type 1 (NT1) is a chronic neurological disease character-
ized by irresistible daytime sleepiness, disturbed nocturnal sleep, and
cataplexy associated with the inadequate function of the hypothalamus2618 Tallinn, Estonia.
en access article under the CC BY-NC(Peyron et al., 2000; Thannickal et al., 2000; Partinen et al., 2014). The
major neuropathological features of NT1 are loss of orexinergic neurons
and an increased gliosis in the posterior hypothalamic nuclei (Partinen
et al., 2014). Increased levels of pro-inﬂammatory cytokines have
been associated with (spontaneously occurring) idiopathic (sNT1) and
Pandemrix vaccine-induced narcolepsy (Pdmx-NT1) close to disease
onset (Lecendreux et al., 2015). Pandemrix (Pdmx) is an inﬂuenza vac-
cine used during the H1N1 2009 swine inﬂuenza A(H1N1) pandemic
and was distributed to over 30 million people in EU/EEA countries-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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vaccine-associated NT1 had been reported to the European Medicines
Agency. Epidemiologic and clinical studies conducted in different coun-
tries including Finland, Sweden, Ireland, England, Norway, and France
have conﬁrmed the association of NT1 in children and adolescents
with the AS03-adjuvanted Pdmx (Partinen et al., 2014; Sarkanen et al.,
2017). Subsequently, wild-type inﬂuenza A(H1N1) infections in China
were associated with narcolepsy (Han et al., 2013, 2011). Along with
the pandemic A(H1N1) infection, seasonality and post-infectious prim-
ing by upper respiratory tract viruses and streptococci have been sug-
gested as triggers of autoimmune response that leads to NT1 in
genetically susceptible individuals (Aran et al., 2009; Longstreth Jr
et al., 2009).
Genome-wide association studies have revealed a strong association
of narcolepsy with the T-cell receptor alpha locus (Hallmayer et al.,
2009) and especially with Major Histocompatibility Complex (MHC)
class II DQB1*06:02 alleles (Bonvalet et al., 2017; Tafti et al., 2014).
DQB1*06:02 is present in approximately 30% of Finnish and Swedish
populations (Bomﬁm et al., 2017). In Finland, all patients with Pdmx-
NT1have been positive forDQB1*06:02 (Partinen et al., 2014). The latter
immune haplotype is also strongly associated with the Pdmx-NT1 in
Sweden (Bomﬁm et al., 2017). In another series of 522 patients with
narcolepsy and cataplexy from different countries, only 9 patients
(1.7%) with low levels of orexin (OX) in cerebrospinal ﬂuid (CSF)
were DQB1*06:02 negative (Han et al., 2014). It was also suggested
that cross-reactive epitopes to Pdmx vaccine antigens may exist in
NT1 diseased as a signiﬁcant proportion of HLA-DQB1*0602–positive
Finns diagnosed with NT1 and with a history of H1N1 vaccination
were immunoreactive to OX receptors (Ahmed et al., 2015). However,
it still is unclear whether OX-positive neurons and/or their neighboring
cells express OX receptors that could be targets for the immune re-
sponse in NT1 (Valko et al., 2013; Vassalli et al., 2015). The antibody
levels to viral nucleoprotein (NP), a Pdmx vaccine antigen, were in-
creased in NT1-diseased carrying the HLA DQB1*06:02 allele (Vaarala
et al., 2014), whereas the role of this and other circulating (including in-
trathecal) autoantibodies in NT1 pathogenesis is not fully understood
(see list of previously identiﬁed antigens in Table S1). Although NT1-
related autoantibodies are found in some patients, the clinical response
to intravascular immunoglobulin (IVIG) has been hard to predict
(Knudsen et al., 2012). Likewise, use of the drug rituximab might have
only short-lasting beneﬁcial effects in NT1 (Sarkanen et al., 2016).
Recent advances in proteomics (immunomics) have made it possi-
ble to study the adaptive immune response in various diseases in
great detail and at a high resolution (lately reviewed in: (Ayoglu et al.,
2016, Wu et al., 2016). We and others have suggested a strategy of
high-throughput sequencing-assisted epitope mapping directly onTable 1
Description of samples studied.
Characteristics Narcolepsy (NT1) patients
Pdmx-NT1
Group size (n) 10
Gender (female/male) 5/5
Pandemrix vaccination 11/2009–1/2010
Sample collection 2011
Median age at onset (y) 13
Median age at sampling (y) 14
Unambiguous cataplexy 10/10 (100%)
MSLT mean SL (range) 2.0 (0.4–4.3)
SOREMPS mean (range) 3.7 (2–5)
HLA DQB1*0602 (%) 10/10 (100%)
CSF-orexin b 150 pg/mL (lower 1/3 limit in Finland) 7/7 (100%)
HC- healthy control, H1N1-HC – H1N1 infected, Pdmx-HC– Pandemrix-vaccinated, NT1- narco
(sNT1) samples), NA – not available, SL – sleep latency,MSLT – Multiple sleep latency test, SOR
a Gender of two Pdmx-HC is unknown.
b Four out of 6 sNT1 patients were vaccinated after they had been diagnosed with NT1.serum for biomarker discovery and disease detection based on the
idea that self- and environmental (exposome) antigens are reﬂected
in the immune response proﬁles (immunoproﬁles) (Anastasina et al.,
2017; Christiansen et al., 2015; Ionov, 2010; Xu et al., 2015). Hence,
the proﬁling of antibody response repertoire with high-density random
peptide/polypeptide display methods could be a novel mean to charac-
terize and classify human diseases in an unbiased manner according to
the molecular/cellular targets relevant for the disease.
In the present study, we have used themimotope-variation analysis
(MVA) method to immunoproﬁle autoantibody repertoires in patients
afﬂicted by NT1 and in controls. We had access to the clinical cohorts
composed of 16 NT1 (sNT1 (n = 6) and Pdmx-NT1 (n = 10)) cases,
where all NT1-diseased subjects carried the HLA DQB1*06:02 allele,
and apart from 2 sNT1 patients, all had been vaccinated with Pdmx.
For reference, we used three well-deﬁned control groups: 16
Pandemrix-vaccinated healthy controls (Pdmx-HC), 16 H1N1-infected
Finnish subjects (H1N1-HC), and 16 healthy Estonian donors (HC –
healthy controls) (Table 1). Our data revealed complex patterns of im-
mune response in all patient groups including novel epitope sequences
present in sera of Pdmx-NT1 and H1N1-HC. One such peptide epitope
was identiﬁed as belonging to the prostaglandin D2 receptor (DP1)
that together with its ligand prostaglandin D2 (PGD2) is involved in
sleep regulation in humans and experimental animal models (see ref.
in Urade and Hayaishi (2011)).
2. Materials and Methods
2.1. Vaccines
Pandemrix vaccine is derived from X-179A, a reassortant of hemag-
glutinin (HA), neuraminidase (NA) and polymerase acidic protein (PA)
of A/California/07/2009 and X-157H3N2 in a PR8 backbone (Jacob et al.,
2015; Nicolson et al., 2012; Robertson et al., 2011). The vaccine compo-
sition can be found summarized by European Medicines Agency and
GlaxoSmithKline plc (European Medicines Agency, 2009).
2.2. Study Population
The present study comprises a total of 64 individuals (Table 1). Alto-
gether, 16 serum samples of H1N1-infected military servicemen (H1N1-
HC), 16 serum samples of age/sex-matched Pandemrix-vaccinated
healthy controls (Pdmx-HC) were kindly provided by National Institute
of Health andWelfare, Finland. 16 serumsampleswere collected frompa-
tients with H1N1-induced (Pdmx-NT1) and sporadic narcolepsy (sNT1).
Four out of 6 sNT1 patients were vaccinated with Pdmx after they had
been diagnosed with NT1. Narcolepsy patients were diagnosed at theHealthy controls (HC)
sNT1 Pdmx-HC H1N1-HC Other HC
6 16 16 16
5/1 12/2a 0/16 10/6
11/2009-1/2010b 11/2009-1/2010 – –
2011 2011 2011 2009
18 – – –
22 NA 21 34.5
6/6 (100%) – – –
2.6 (0–7.5) NA NA NA
2.7 (2–4) NA NA NA
6/6 (100%) NA NA NA
5/5 (100%) NA NA NA
lepsy type 1 (including 10 Pdmx-induced NT1 samples (Pdmx-NT1) and 6 sporadic NT1
EMPS – Sleep onset REM periods as deﬁned by the American Academy of Sleep Medicine.
49H. Sadam et al. / EBioMedicine 29 (2018) 47–59Finnish Narcolepsy Research Center (Helsinki Sleep Clinic, Vitalmed Re-
search Center) by experienced neurologists with a special competence
in sleep medicine. All narcolepsy patients had NT1 as deﬁned by the
American Academy of Sleep Medicine international criteria of sleep
disorders version 3. All excessively sleepy patients with NT1 had un-
ambiguous cataplexy and an abnormal MSLT (sleep latency b8 min
and at least 2 sleep onset REM periods; Multiple Sleep Latency Test) re-
cording after a polysomnography. Twelve of the 16 patients had their
CSF-orexin levels measured using the standardized Phoenix RIA
method with Stanford reference. All except one had CSF-orexin levels
b110 pg/mL (one woman with clearly abnormal MSLT and unambigu-
ous cataplexy had CSF-orexin level of 127 pg/mL).
Control serum specimen for the study included 16 serum samples
from Blood Centre, North Estonian Regional Hospital, Estonia, collected
in 2009 prior to the swine inﬂuenza pandemic (other HC). Sera were
stored at−135 °C until use.
2.3. Ethical Permissions
The patients have participated in the NARPANord narcolepsy study
(Academy of Finland, grant nr. 260603), and they have given a written
informed consent. The serum samples of H1N1-infected military ser-
vicemen and serum samples of the Pdmx-vaccinated healthy controls
were provided by the National Institute of Health and Welfare,
Finland. The ethical permissions were approved by the Ethics Commit-
tee of the Hospital District of Helsinki and Uusimaa, Finland.
2.4. Mimotope-Variation Analysis
For qualitative and quantitative characterization of humoral immune
response from sera samples, we used an in-house developed
mimotope-variation analysis (MVA) method. Fig. 1A provides an over-
view of the process. In brief, a random 12-mer peptide phage library
(Ph.D.-12, NEB, UK) was used according to the manufacturer's protocol.
2 μL of serum sample was incubated with 2.5 μL library (~5 × 1011) and
immunoglubulin G (IgG) fraction was recovered using protein G-coated
magnetic beads (Thermo Fisher Scientiﬁc). The unbound phage particles
were removed by extensive washes with TBS-T (TBS + 0.1% [v/v]
Tween-20). Selectively captured phage DNA was analyzed by using next
generation (Illumina) sequencing with barcoding primers (Islam et al.,
2014). For that, DNAwas extracted by using standardNaI/EtOHprecipita-
tion method and enriched by PCR ampliﬁcation using primers enriched
with adapters for the sequencing reaction that ﬂank the variable region
at the end of pIII in M13KE vector (Fw: 5′-AATGATACGGCGACCACCGAG
ATCTACACTGATCTAGTGGTACCTTTCTATTCTCA*C*T*C*T-3′ Rv: 5′-CAAG
CAGAAGACGGCATACGAGATNNNN(NN)CCCTCATAGTTAGCGTAACG-3′).
PCR products were puriﬁed using the QIAquick PCR Puriﬁcation Kit
(QIAGEN), and the concentration of DNA with Illumina adapters was es-
timated by Qubit Fluorimeter (Invitrogen) according to the manufactur-
er's protocol. Sequencing was performed using Illumina HiSeq and 50-
bp single end reads. Samples were analyzed at least in duplicates to en-
sure reproducibility. To evaluate the data reproducibility, we compared
peptide abundance in two replicates using Pearson's correlation coefﬁ-
cient test (r value higher than 0.90, p b .0001).
2.5. Sequence Data Analysis
Every read that was considered valid by the Illumina HiSeq control
softwarewas prepared for further analysis by trimming. In brief, sequence
reads of 50 bp were accompanied with a 4-bp tag to assign each read
uniquely to one out of 48 multiplexed samples. After demultiplexing
there were millions of sequence reads for each sample. Each read
consisted of a 36-bp random insert region and a constant region. We
discarded the reads with mismatches in ﬂanking 4 bases of the constant
region. Sequences fromwild-type phageswith no random insertwere ex-
cluded. Next, we translated all the random insert regions in reads intopeptide sequences of length 12aa. All non-translatable sequences were
discarded. To reduce the effect of ampliﬁcation and sequencing errors,
only those peptide sequences were kept that had at least two copies se-
quenced per sample. In order to compensate for the different numbers
of reads per sample normalization of read countswas performed. All sam-
pleswere trimmed to 3million reads (RPMunits). The resulting datawas
represented as a cross-table where each row corresponded to a different
12mer peptide, each column corresponded to a different sample, and
each cell showed the read count of the peptide in the respective sample
measured in RPM-units. According to the manufacturer (NEB), naïve li-
brary contained up to 109 different sequences. For reasoned cost pur-
poses, the estimated outcome of sequence data represented 0.1% of the
initial library input containing up to 2.8 × 106 different peptide sequences
per sample. Complete analysis of sequence diversities obtained by MVA
remains out of the scope of the current study.
2.6. Clustering Workﬂow
The main assumption was that every obtained peptide sequence
mimics the target of an antibody. The sequence reads of one sample
often included many copies of the same peptide sequence. The read
counts of a peptide could range from1 to thousands. To reveal recognition
patterns (epitope motifs) which were enriched in the cases compared to
controls, we used SPEXS2 software (https://github.com/egonelbre/
spexs2; (Vilo, 2002, Brazma et al., 1998)). For clustering the peptides
with motifs and generating mimotope regular expression and sequence
logos, the “motifTree” tool was used (Kruup, 2013). The Multiple EM for
Motif Elicitation (MEME-MAST) algorithm (Bailey and Elkan, 1994;
Bailey and Gribskov, 1998) was used to align peptides to proteins. For B
cell epitope mapping IEDB 3.0 database was used (Vita et al., 2015).
2.7. Statistical Analysis
All statistical analyses (ANOVA, t-Test, correlation analyses, Chi-
square test) were done using MedCalc software (MedCalc Statistical
Software version 17.0.4 (MedCalc Software bvba, Ostend, Belgium;
https://www.medcalc.org; 2017)). For visualization of peptide abun-
dance across samples, peptide frequency values were converted to
heatmap images (Tagged Image File) with Excel Visual Basic for
Applications (VBA) scripts. For visualization of selected peptide
set alignment proﬁle on proteins of interest Excel VBA script was used.
The protein sequence was scanned with every peptide and at every po-
sition where the peptide aligned with it in at least four perfectly
matching positions, one was added with its frequency. For random ref-
erence proﬁle, amino acid sequence of each peptide was randomized
and scanned using the same rules over the target sequence.
2.8. Inﬂuenza Virus Serology
Levels of inﬂuenza-speciﬁc IgG antibodies were determined by the
enzyme-linked immunosorbent Vir-ELISA anti-H1N1/H3N2 IgG assay
(Inﬂuenza virus type A IgG ELISA test system, Euroimmun), carried
out in accordance with the manufacturer's speciﬁcations. Absorbance
was measured at 450 nmwith SpectraMax Paradigm.
2.9. Peptide ELISPOT
For peptide ELISPOT the following peptides were designed:
peptide #1 - RVLAPALDSWGTGGGDYKDDD{LYS(BIOTIN)}
(Genescript)
peptide #2 - LPKFSAPSASGPGGGDYKDDD{LYS(BIOTIN)}
(Genescript)
peptide #3 - ESTRYQLWLPHQGGGDYKDDD{LYS(BIOTIN)}
(Genescript)
control peptide - AVLAAALASWGTGGGDYKDDD{LYS(BIOTIN)}
(Genescript)
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nitrocelluose coated slides (10485323, Whatman) by SpotBot® 4
(Arrayit). For primary antibody human precleared serum (1:100) was
used, for secondary antibody rabbit anti-human IgG (H&L) (HRP)
(Abcam) was used. All incubations were done for 1 h at room tempera-
ture. Results were scanned using Ettan DigeImager (GE Healthcare Life
Sciences) and images calculated using ImageQuant software version
8.1 (GE Healthcare Life Sciences).
2.10. Cancer Cells, Human Mesenchymal Stem Cells (hMSC) and Post-
Mortem Tissues
Immortalized glioblastoma multiforme cells (human glioma cells -
hGC) (kind gift of Prof. Aavo-Valdur Mikelsaar, Estonia), humanFig. 1. Humoral immune response studied using the mimotope-variation analysis (MVA) me
peptide phage display analysis. A random peptide display library (PhD12) was used which c
phage major coat protein pIII (NEB). For MVA, sample-speciﬁc IgG proteins (antibodies, Huma
displayed peptides and the IgG-phage complexes were captured to protein G magnetic beads,
were lysed and DNA ampliﬁed with primer sequences containing a tag with a unique barcod
primer set homologous to the M13KE vector sequences that ﬂank the random peptide coding
were speciﬁc to Pmdx-infected, -vaccinated and NT1-diseased individuals was carried out
diseased (Peptide proﬁle analysis). On average, MVA generated 1.8 million peptide sequences
(total abundance; number of reads) per sample. Altogether, a peptide data set with N16 mi
revealed highly divergent patterns (immunoproﬁles) across study cohorts. The fraction of to
peaking immune reactivity of each sample - was analyzed for variance. Top2500 peptide datas
display the sequence distribution of unique peptides across all samples analyzed. The left pie
individual whereas ~14% of the peptide sequences were shared between samples, out of thes
samples. The right pie (red) displays the distribution of shared 16,844 peptide sequences out
in N10 samples. The four pie charts (below) exemplify the peptide proﬁle structures in diffe
peptides common to one or more samples of a clinical cohort. Blue - represents unique peptid
all immunoproﬁles. Top 2500 peptides were analyzed to assess the range of individual peptide
indicated, between one to two thousand peptides were individual-speciﬁc, whilst the most
across samples. Range of unique peptide variations was similar across all study samples. D. H
study samples. Peptide proﬁles were individual-speciﬁc with a highly varying abundance. Eac
peptide with a unique primary structure. Abundance is presented as counts in logarithmic sca
at lower abundance. Shown are peptide proﬁles that were common to 3–10 individuals. Abbrev
trol; H1N1-HC – H1N1 infected; Pdmx-HC- Pandemrix-vaccinated; NT1- narcolepsy type 1 (incneuroblastoma cell line Kelly (ATCC) and human mesenchymal stem
cells (hMSC) (isolated from human subcutaneous adipose tissue as de-
scribed (Jaager and Neuman, 2011)) were grown in Dulbecco's modiﬁed
Eagle'smedium(DMEM(PAA)) containing 10% fetal bovine serum(PAA),
1 mg mL−1 penicillin (PAA) and 0.1 mg mL−1 streptomycin (PAA). All
cells were cultured at 37 °C in 5% CO2. The identity of hMSC was con-
ﬁrmedbyusing cellmorphology andﬂowcytometrymethods for analysis
of cell surfacemarkers: CD73+/CD90+/CD105+/CD45−/CD34− (Kauts
et al., 2013). For treatments, hMSCs were grown with media containing
IL-1β (1 ng/mL), IFNγ (2 ng/mL) for 8 h, or PGD2 (10 μM) for 1 h.
Human post-mortem tissues were procured from the North-
Estonian Regional Hospital, Tallinn, Estonia. All experiments with
human tissueswere donewith the approval of the local ethical commit-
tee (license no. 2234, date of issue 09.12.2010).thod. A. Schematic drawing of the workﬂow in MVA. MVA is a high-throughput random
ontained 10^9 different 12-mer peptide sequences introduced to the N-terminus of the
n IgG fraction) present in human sera of interest are allowed to interact with the phage-
while the unbound phages were washed away (Peptide library display). Captured phages
e sequence and the ﬁnal amplicons were pooled for NGS analysis (HTS sequencing). The
sequence was used to amplify a 50-bp fragment. Data analysis to classify peptides that
by comparing the proﬁles of peptides (mimotopes) from diseased to those from non-
with unique structure (divergence) totaling 2.8 million peptide sequences in abundance
llion sequences (Totpep) with unique structure was generated. B. Analysis of peptides
p 2500 peptides with unique structure and highest values of abundance - reﬂecting the
et contained altogether 160,000 sequences out of which 121,142 were unique. Pie charts
(blue) displays the proportion of shared vs. unique peptides: ~86% were unique to one
e ~8.5% were common to 2 samples, 5% to 3–10 samples and 0.5% were detected in N10
of which ~60.7% were common to 2 samples, 35.7% to 3–10 samples and 3.6% were seen
rent clinical cohorts. The size of each pie piece is proportional to the number of unique
es, red - the most shared. C. Individual variation in peptide divergence is characteristic to
variation across study cohorts. Blue dots mark peptide divergence in a single sample. As
common peptides (shared by N10 individuals) ranged in divergence from tens to 350
eat map image of a random fragment of MVA proﬁle encompassing 400 peptides across
h column represents the peptide proﬁle of a single individual, and each line represents a
le (in log); black colour depicts peptides captured at higher abundance, and white those
iations: Abundance – peptide frequency;Divergence – all unique peptides;HC- healthy con-
luding 10 Pandemrix-induced NT1 samples).
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For immunoﬂuorescence analysis, cells grown on glass inserts were
ﬁxed using 4% PFA (Scharlau) for 15 min and blocking of the unspeciﬁc
reactivity was done with 5% BSA. The antibodies used included: anti-
DP1 (Abnova; 1:500), precleared human sera (1:400), and the second-
ary Alexa Fluor 488 and 647 (Invitrogen, 1:2000) antibodies. For epitope
blocking peptide #1 was used in ﬁnal concentration 6.6 μg/mL. Hoechst
33342 (Invitrogen) was used to detect cell nuclei. Imaging was done
using Nikon Eclipse 80i microscope.
Sequences (RVLAPALDSWGT and DYKDDDDK (ﬂag)) were inserted
at the N-terminus of the pIII of the M13KE phage by in vitro mutagene-
sis PCR using primers s1 5′GCTGGATAGTTGGGGAACCGGTGGAGGTTCG
GCCGAAAC3′, as1 5′GCCGGAGCTAGTACACGAGAGTGGGAGTAAAACG
GTACC3′,
s2 5′GCTGGATAGTTGGGGAACC3´, as2 5`GCCGGAGCTAGTACACG3′; s3
5′GATGATGATAAAGGTGGAGGTTCGGCCGAAAC3′, as3 5′ATCTTTATAAT
CAGAGTGGGAGTAAAACGGTACC3′; s4 5′GATGATGATAAAGGTGG3′, as4
5′ATCTTTATAATCAGAGTGG3′. PCR reactions were carried out with
phusion Hot Start II High-Fidelity DNA Polymerase (ThermoScientiﬁc).
Constructs were veriﬁed by sequencing. For Western blot analysis, 30 μg
of protein lysate or 1 × 1013 phage particles were resolved on 10% SDS–
polyacrylamide gels and transferred onto PVDFmembranes (Amersham)
for 1.5 h using BioRad wet blotter in standard Towbin buffer. The
membrane was blocked with 5% nonfat milk (AppliChem), incubated
overnight with the following primary antibodies: anti-DP1 (St. John Lab-
oratory, 1:1000), anti-GAPDH (Sigma, 1:10,000), precleared human sera
(1:500). The epitope blocking peptide #1was used in ﬁnal concentration
6.6 μg/mL. The membrane was incubated for 1 h at room temperature
with the secondary anti-mouse, anti-rabbit, or anti-human IgG antibodies
(Abcam; dilution 1:10,000). The ECLfemto kit (Amersham) was used for
detection of immunoblotted target proteins.
2.12. RNA Extraction, RT-PCR and qRT-PCR
Total RNA from human brain parts was extracted using RNAWiz
(Ambion) as recommended by the manufacturer. Total RNA from cells
was isolated using TRIzol® Reagent (Invitrogen) according to the manu-
facturer's instructions. One microgram of RNA was reverse transcribed
into cDNA using SuperScript III ﬁrst strand cDNA synthesis kit
(Invitrogen) according to the manufacturer's instructions. The resulting
cDNAs were used as templates for subsequent RT-PCR reactions. RT-PCR
was carried out using FIREPol® DNA polymerase (Solis Biodyne), 40 am-
pliﬁcation cycles and an annealing temperature of 58 °C. Ampliﬁcation of
the housekeeping gene GAPDH was performed for 25 cycles using
FIREPol® DNA polymerase (Solis Biodyne) and used as an internal con-
trol. Used primer sequences: PTGDR sense 5′ATGAAGTCGCCGTTCTAC
C3′, PTGDR antisense 5′CATGAAGAAGGCGAAGGCTTG3′, GAPDH sense 5′
GAAGGTGAAGGTCGGAGT3′, GAPDH antisense 5′GCATGGACTGTGGTCA
TGAG3′. IL-1β sense 5′GGGCCTCAAGGAAAAGAATC3′: IL-1β antisense 5′
TTCTGCTTGAGAGGTGCTGA3′, IFNγ sense 5′CTGTTACTGCCAGGACCCA
T3′, IFNγ antisense 5′TTTCTGTCACTCTCCTCTTTCCA3′.
3. Results
3.1. Autoimmune Response Proﬁles Across Cohorts are Highly Heterogeneous
We performed MVA by selecting peptide antigens from random
phage library (PhD12, NEB) with 10^9 different 12-mer peptide se-
quences based on their high avidity of interaction to antibodies in sera
(Fig. 1A). A total dataset of 16 million peptides with unique sequences
was generated. The data structure analysis of Top2500 peptide dataset
(themost abundant peptides across individual samples) revealed that al-
though these peptideswere largely individual-speciﬁc (Fig. 1B andD), the
study cohorts shared a fraction of common characteristics across Top2500
features (Fig. 1B). The remarkable heterogeneity of antigenic reactivitybetween individuals has also been noted previously (Zandian et al.,
2017). However, the distribution of peptides according to the frequency
was found to be similar in the different clinical subsets (Fig. 1C).
3.2. H1N1-speciﬁc Immunoproﬁles are Largely Shared Between Pdmx-
Vaccinated and Subjects Infected With H1N1
To evaluate the extent to which the presence of H1N1-speciﬁc pep-
tides was restricted to speciﬁc clinical subsets, we assayed responses to
H1N1 infection and Pdmx-vaccination using type A inﬂuenza ELISA
(Quantum) diagnostic tests. High-titer responses to inﬂuenza A virus
major antigens (including H1N1) were evident for both Pdmx-
vaccinated and H1N1 naturally infected individuals (Fig. 2A). The hu-
moral response to seasonal ﬂu (A/H1N1 and A/H3N2) was relatively
weaker in NT1-diseased as compared with Pdmx-HC individuals as de-
termined by using a commercial ELISA test (p b .001). This was in slight
contrast to earlier ﬁndings reporting that Pdmx-NT1 patients had
higher median levels of anti-H1N1 antibodies than controls (Lind
et al., 2014), andmay reﬂect the characteristics of the samples collected
(see Table 1,Materials andmethods). Next, we assessed the reactivity of
the sera to protein fragments representing the four major antigens of
H1N1 virus proteome (strain A/California/7/2009). MVA data analyses
of Top2500 peptide data set revealed 4 antigenic regions for hemagglu-
tinin (H1N1/HA, C4RUW8), 5 for neuraminidase (H1N1/NA, C3W6G3),
3 for nucleoprotein (H1N1/NP, B4URE0), and 6 for polymerase acidic
protein (H1N1/PA, I6THC5), some of which corresponded to known im-
munogenic epitopes from IEDB (http://www.iedb.org/; Fig. 2B). Statisti-
cally distinct coverage proﬁleswithdifferent peaks onH1N1HA, NA, NP,
and PA antigens were obtained from analysis of Top2500 peptide data
sets of H1N1-HC, Pdmx-HC and NT1 samples (Fig. 2C). Data showed
that the most commonly shared epitopes raised by the anti-Pdmx/
anti-H1N1 immune response were found in the C-terminal region of
H1N1/HA (C4RUW8) locating between amino acids 521 to 531
(Fig. 2B–C), directly before a proven T cell-antigenic region in HA be-
tween amino acids 527–541 of A/California/04/2009 (H1N1, (Schanen
et al., 2011)). About 700 peptides from the total peptide dataset cluster-
ing to motif with sequence consensus E[ST].R.[QM] were highly abun-
dant in H1N1-HC, and relatively infrequent in Pdmx-HC and NT1
samples as compared with HCs (Fig. 2D).
3.3. Examination of Identiﬁed NT1-speciﬁc Autoantigens in MVA Dataset
Next we determined peptides that were different between the clin-
ical study groups to examine whether they were consistent with the
prior knowledge of Pdmx-NT1-speciﬁc immunogenic epitopes. For the
study, we used an exhaustive sequence pattern search (SPEXS -
https://github.com/egonelbre/spexs2; (Vilo, 2002, Brazma et al.,
1998)) gene ontology analysis, combined with the interrogation of the
presence of known autoantigens previously identiﬁed in Pdmx-NT1 dis-
ease (Table S1(Ahmed et al., 2015, Bergman et al., 2014, Cvetkovic-
Lopes et al., 2010, De La Herran-Arita et al., 2013, Haggmark-Manberg
et al., 2016, Katzav et al., 2013, Zandian et al., 2017)). Thus, we were
able to conﬁrm statistically signiﬁcant patterns of epitope recognition
in the samples. Particularly, we identiﬁed epitopes resembling those
in the N-termini of OX (4/16) and OX1R/2R (2/16; 4/16), in mitogen-
activated protein kinase 7 (MAP3K7) (amino acids 318–328; 3/16)
and in 5′-nucleotidase cytosolic IA (NT5C1A) (amino acids 35–48; 2/
16), as well as in B-cell lymphoma 6 protein (BCL6), encompassing
amino acids 279–288 in 6 out of 16 sera samples of NT1 diseased
(Fig. 3, Table S1). According toMVA data, none of the previously identi-
ﬁed antigens was prominently detected across NT1 diseased and were
also common also to HC if less stringent statistical power criteria were
used (Fig. 3). In contrast, we found no evidence of stratifying peptides
with consensus sequences mimicking tribbles pseudokinase 2 (TRIB2),
neuropeptide glutamic acid- isoleucine/α-melanocyte-stimulating hor-
mone (NEI/aMSH), or others that were reported by earlier studies
Fig. 2. A novel common epitope of HA antigen of A/H1N1 in seasonal infection carriers and Pdmx-vaccinated individuals, encompassing a proven T cell- antigenic region. A. The humoral
response to seasonal ﬂu (A/H1N1 and A/H3N2) was relatively weaker in NT1-diseased as comparedwith Pdmx-HC individuals as determined by using a commercial ELISA test (p b .001).
The presence of IgG antibodies against HA and H3N2was assessed in sera samples ofHC, H1N1-HC, Pdmx-HC and Pdmx-NT1 by ELISA (Inﬂuenza virus type A IgG ELISA, Euroimmun). The
HC samples were collected prior to A/H1N1 outburst in Estonia, before the fall 2009. Blue circlesmark individuals of the study cohorts; red dotsmark the mean values; lines depict median
values; inner whiskersmark conﬁdence interval for themean; boxesmark upper and lower quartiles; outer whiskersmark the maximum andminimum values (excluding the outliers). P-
values were calculated by ANOVA and are markedwith asterisks. The cut-off value for ELISA was 16 RU/mL. Labels at the top of box plots demark the clinical origin of the sample. B. MVA
predictedH1N1 epitopes partially overlappedwith previously describedH1N1 (A/California/08/2009(H1N1)) B cell speciﬁc epitopes from IEDB (http://www.iedb.org/). Top2500 peptide
dataset containing 121,142 unique sequences was used to delineate the predominant epitopes of H1N1/HA (GI: 238,623,304), H1N1/NA (NA, GI:758899360), H1N1/NP (NP,
GI:229891180) andH1N1/PAproteins in study samples. 9657 peptides from the studied dataset satisﬁed the selection criteria that thesewere not present in theHC samples. Speciﬁc align-
ment proﬁles for each of the A/H1N1 protein antigens were calculated with the criterion that the abundance of a peptide was to be 2-fold higher over random. C. MVA immunoproﬁles
predicted a novel epitope in the C-terminal region of HA encompassing amino acids 521–531 and with the sequence ESxRxQ that was common to both seasonal infection carriers and
Pdmx-vaccinated individuals. The graphs show antigen-speciﬁc proﬁles of overall peptide abundance where the number of peptides were counted for each amino acid position for the
following proteins: hemagglutinin (H1N1/HA, C4RUW8), neuraminidase (H1N1/NA, C3W6G3), nucleoprotein (H1N1/NP, B4URE0) and polymerase acidic protein (H1N1/PA_I6THC5).
Amino acid sequence of the proteins is depicted on the x-axis. Marked with asterisks are regions where set calculation criteria were satisﬁed. Detailed analysis of immunoproﬁles of
H1N1 antigens revealed a novel immunogenic region of HA encompassing amino acids 521–531 that corresponds to the earlier experimentally determined A/Puerto Rico/8/1934
(H1N1) HA520–530 CTL epitope (Gianfrani et al., 2000) and is partially overlapping with broadly reactive CD4+ T cell epitope: HA527–541 of A/California/04/2009(H1N1) (Schanen
et al., 2011). Peptides aligning to 521–531 ofHA cluster to aminimal consensus sequence E[ST].R.[QM] by sequence homology alignment. D.Heatmap image of immunoproﬁles of peptides
with consensus E[ST].R.[QM] across study samples. The total peptide data set was examined for the peptides with unique structure clustering to E[ST].R.[QM] motif. About 700 peptides
with enriched abundance in H1N1-HC, Pdmx-HC or Pdmx-NT1 samples were found to cluster to the motif. The data of 700 peptides is presented on the heat map image. Each line rep-
resents peptides with unique sequence structure. The colour intensity of each cell corresponds to the peptide abundance (presented in log value). Black represents peptides captured at
higher abundancewhereaswhite represents peptides captured at lower abundance. Each column represents a peptide proﬁle from a single sample. Labels at the top of the panels indicate
the clinical origin of the sample. Abbreviations: Randomalignment – amino acid sequences of peptides under analysiswere randomized and aligned to respective protein coding sequence;
Total abundance - the number of peptides counted for deﬁned amino acid positions; HC– healthy control; H1N1-HC – H1N1 infected; Pdmx-HC- Pandemrix-vaccinated; NT1- narcolepsy
type 1 (including 10 Pandemrix-induced NT1 samples).
52 H. Sadam et al. / EBioMedicine 29 (2018) 47–59(Table S1). These data allowed concluding that apart from the BCL6 re-
lated subset, peptides corresponding to previously identiﬁed
autoantigens had relatively little discriminative power, suggesting also
that these antigenswere either rare or recognized promiscuously in pa-
tient groups with a clinical and ethnical heterogeneous background.
3.4. A Deﬁned Set of Peptides Derived From DP1 Acts as Antigenic Epitopes
in NT1
In analyses of the peptides that were unique among the disease
groups, we observed that the Top2500 dataset contained N1300 pep-
tides with a high enrichment in NT1 (Fig. S1A–B). The most abundant
peptide having the sequence RVLAPALDSWGT showed a high sequence
homology within the second extracellular loop region in the human
prostaglandin D2 receptor DP1 (Q13258). This region in DP1 is pre-
dicted to function in ligand recognition (Avlani et al., 2007; Nagata
et al., 2017) and is not conserved in mouse and rat (Fig. 4A). Extractionof all peptides from the total dataset having the highest homology to
RVLAPALDSWGTand toDP1 revealed a set of 4428 uniquepeptides con-
taining the RxxxPxxD (RPD) consensus sequence that discriminated the
NT1 samples from controls (p b .0001, ANOVA, Fig. 4B–C).We then also
determined that the 2157 RPD-containing peptides out of 4428 (Fig. 4B)
had a high sequence homology to DP1 protein where the bona ﬁde
immunodominant epitope with sequence RVLAPALD encompassed
amino acids 94 to 101 in DP1 (Fig. 4D). Interestingly, according to the
IEBD database (www.iedb.org/), four MHC-I binding epitope regions
of DP1 encompassing amino acids 132–140 (ID: 716767), 145–156
(ID: 637966), 195–203 (ID: 727099) and 303–311 (ID: 697995) have
been deﬁned. The latter (303−311) encoded another extracellular do-
main of DP1 that was also deﬁned by us a potential target of B cell re-
sponse (Fig. 4D).
To validate the data, we employed different methods and measured
the serologic response to peptides carrying the RPD consensus sequence
using sera samples of the study (Fig. 5–6). In line with previous reports
Fig. 3.Heterogeneity of the immune response to delineated antigens is apparent at the individual level. The total peptide data set was examined for peptides with homology to different
antigens (see Table S1). Homology alignment analysis resulted in delineating six minimal consensus motifs with homologies to epitopes deﬁned by previous studies. Namely, LPxTNxS
(HCRT, O43612), RDxxYP (HCRTR1, O43613), SxLNxTxN (HCRTR2, O43614), KxxxPSAS (BCL6, P41182), STNxS (MAP3K7, O43318), LAxSxKP (NT5C1A, Q9BXI3), (Table S1). Datasets
from different study cohorts were analyzed for the presence of peptides containing the 6 motifs and ROC analyze was performed at threshold values: a) speciﬁcity 100% (sensitivity
50%), b) speciﬁcity 90%, (sensitivity 63%), c) speciﬁcity 85% (sensitivity 69%). Note that the ensemble snapshots from MVA data did not distinguish between the possible scenarios of
each individual antigen motif in single individuals. Individual samples are colour coded. White circles indicate that peptides with abundance values clustering to one or more
aforementioned motifs were below threshold. Colored circles indicate peptides with abundance values clustering to one or more aforementioned motifs were above threshold. None of
the motifs displayed a statistically signiﬁcant association with many other known antigens (see the list of antigens in Table S1). This negative result may be due to a limited statistical
power of delineated antigens, but also due to the heterogeneity of autoantibody repertoires in different individuals. Abbreviations: HC- healthy control; H1N1-HC – H1N1 infected;
Pdmx-HC- Pandemrix-vaccinated; NT1- narcolepsy type 1 (including 10 Pandemrix-induced NT1 samples).
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mRNA across different regions of human brain, in human glioma (hGC),
and normal mesenchymal stem cells (hMSCs) (Fig. 5A). Treatments of
hMSCswith the ligand prostaglandin D2 increasedDP1 expression,whilst
the pro-inﬂammatory cytokines interleukin 1β and interferon γ (IL-1β
and IFN-γ) either slightly increased or decreased its expression, respec-
tively (Fig. 5B). In contrast, PGD2 strongly reduced IL-1β and IFN-γ ex-
pression suggesting that these cells recapitulate the intact PGD2-DP1
signaling pathway by inducing anti-inﬂammatory responses in the stud-
ied cells (Fig. 5B). Performing phage Western blot assay we conﬁrmed
that MVA predicted DP1-positive Pdmx-NT1 sera showed IgG reactivity
to phages that displayed RVLAPALDSWGT peptides (RVLAPALD-pIII,
Fig. 5C). No speciﬁc reactivity was detected using DP1-negative sera
(Fig. 5C). This peptide target speciﬁcitywas further conﬁrmedbyWestern
blot analysis using Pdmx-NT1 sera where the interactions between
human IgGs and antigen expressing phages were blocked by
RVLAPALDSWGT synthetic peptides (Fig. 5C, Fig. S2). Immunoblot analy-
sis using commercial anti-DP1 polyclonal sera and clinical sera of Pdmx-
NT1, conﬁrmed the presence of DP1 expression in hGC_1 and not in
hGC_2 glial cells and also here speciﬁc blocking effects to the
seroreactivity in the presence of RVLAPALDSWGT peptides were con-
ﬁrmed (Fig. 5D), but not in case of control peptides or irrelevant sera
(Fig. 5C, Fig. S2). Immunocytochemical analyses showed that DP1 was
predominantly localized on the cell surface of hMSC and hGC cells, and
more importantly, was equally well-detected by immunocytochemistry
using commercial anti-DP1 polyclonal sera and Pdmx-NT1 clinical sera
(Fig. 5E). Furthermore, the synthetic peptide RVLAPALDSWGT competed
for the binding of anti-DP1 antibodies present in sera of Pdmx-NT1 dis-
eased (Fig. 5E). Data combined from Western blot and immunocyto-
chemistry analysis suggested that peptide RVLAPALDSWGT could
embed a structural aswell as a linear epitope given that upon competition
it interferedwithDP1-speciﬁc serorecognition of globular aswell as dena-
tured epitopes (Fig. 5D and E).
We next studied whether the peptides identiﬁed here could be de-
veloped to an ELISPOT assay to discriminate sera in different disease
groups. ELISPOT analysis data showed that peptides containing H1N1/
HA-speciﬁc sequence ESTRYQL (peptide_3) discriminated between nat-
urally H1N1 infected and healthy samples with no earlier H1N1 infec-
tion (ANOVA p b .001, Fig. 6A). RVLAPALD (epitope on DP1) and
KAPSAS (epitope on BCL6) (peptide_1 and _2) peptides that were se-
lected upon MVA data, correctly assigned upon ELISPOT analysis theNT1 group from HC samples (ANOVA p b .001, Fig. 6B). Combined
ELISPOT analysis using all 3 peptides, could correctly classify 11 out of
16 NT1 (speciﬁcally - 7 Pdmx-NT1 and 3 NT1) samples across all con-
trols (p b .001 Chi-squared test, Fig. 6C). Notably, majority of the DP1
and BCL6-peptide-positive NT1 samples had undetectable OX ﬁndings
from the related CSFs (with average values of 6.1 pg/mL), whereas
those 4 thatwere negative by our ELISPOTmeasurements, hadOX levels
in respective CSF samples still low but in detectable range (with average
values of 77 pg/mL (Fig. 6C and see Materials and methods). Unlike the
IgG response, the IgM levels in response to the tested peptideswere low
or absent in all studied individuals (data not shown). These ﬁndings
conﬁrmed that peptides carrying the epitope motifs identiﬁed in the
study could be used in ELISPOT analysis to develop a novel multi-
biomarker diagnostic assay for NT1.
4. Discussion
Despite extensive research using biomarker and neurophysiological
approaches, knownheterogeneity amongNT1diseased is not always con-
sistentwith serologicmarker-based subtype classiﬁcation schemes. Using
an unbiased analysis of serum samples from single individuals, we de-
tected a high variance in humoral immune response proﬁles, both in
healthy and diseased people. We found that variance in immunoproﬁles
representing multifactorial heterogeneity of NT1 clearly determined dis-
tinct disease-speciﬁc serological proﬁles.We focused our analysis on pep-
tides speciﬁc to Pdmx-immunized and -NT1 diseased subjects, which
encompassed vaccine antigens and autoantigens in order to have a full
coverage of potential triggers of the disease. Our results show that pa-
tients with NT1 exhibit a speciﬁc immune response to epitopes of recep-
tor DP1. Thisﬁnding highlights the importance of the PGD2-DP1 pathway
in the functioning of sleep-wake homeostasis as suggested by the role of
DP1 in slow-wave sleep (Terao et al., 1998). However, the precise mech-
anism by which PGD2-DP1 signaling may inﬂuence orexinergic neurons
and immune regulation in NT1 requires further studies. In addition,
using MVA-based immunoproﬁling, we discovered epitopes, such as
those of the protein BCL6 speciﬁc for Pdmx-NT1 and sNT1 patient
group. This underscores the complexity of NT1 with different molecular
targets and pathways involved and contributing to the immune response.
Enhanced inﬂammation due to immune systemmalfunction has been de-
tected in human narcoleptics in the regions of OX cell loss (Bassetti et al.,
2010; John et al., 2013; Nishino, 2011; Thannickal et al., 2000, 2003,
Fig. 4. Peptides with minimal epitope motif RxxxPxxD (RPD) are enriched in samples of NT1 and align to the extracellular loop of human DP1. A. Peptide RVLAPALDSWGT found as the
most abundant in Pdmx-NT1 was highly homologous to the second extracellular loop region of DP1 protein. More than 1,300 peptides from the selection of the Top2500 peptide dataset
were enriched in NT1 samples (Fig. S1A–B) where the peptide RVLAPALDSWGT had the highest values of abundance across the Pdmx-NT1 cohort. BLAST analysis revealed that
RVLAPALDSWGT region of DP1 is highly dissimilar in mammals. To identify peptides from Totpep dataset with the highest homology to DP1 and to RVLAPALDSWGT, SPEXS2 software
(https://github.com/egonelbre/spexs2.) was used and the top motif that fulﬁlled both criteria was found to be RxxxPxxD (RPD, a motif deﬁned by three shared amino acids). B.
Peptide sequences containing RPD motif were enriched in immunoproﬁles of NT1 samples. Analyzing the Totpep library, 4428 peptides were identiﬁed from NT1 (including 10 Pdmx-
induced NT1 samples and 6 sNT1 samples) data sets that contained the RPD motif. Box plot depicting that these 4428 peptides (with RVLAPALDSWGT eliminated beforehand as
dominant) contained sufﬁcient information to discriminate between HC and NT1 samples in a statistically signiﬁcant manner a) by their abundance (in log, student t-test p-value b
.0001) and b) divergence (in log, student t-test p-value b .0001). SPEXS2 analysis resulted in 2157 peptides that out of 4428 were highly homologous (with at least 4 consecutive
amino acid matches) to RVLAPALD of human DP1 and discriminated NT1 samples (including 10 Pdmx-induced NT1 samples and 6 sNT1 samples) in a statistically signiﬁcant manner
c) by their abundance (in log, student t-test p-value b .0001) and d) divergence (in log, student t-test p-value b .0001). Six NT1 samples that were not Pdmx-induced were similarly to
Pdmx-NT1 samples discriminated by the set of 4428 peptides from HC. In box plots - blue circles mark the single individuals of study cohorts; red dots mark the mean values; line
marks themedian values; inner whiskersmark conﬁdence intervals for the mean; boxesmark the upper and lower quartiles; outer whiskersmark themaximum and the minimum values
(excluding outliers). C. Heatmap images depicting the immunoproﬁles of the top one thousand NT1-speciﬁc peptides out of 4428 across the clinical study-groups. The data are presented
as heatmap image generated via conditional formatting inMS Excel. Each column represents a peptide proﬁle froma single individual. Each line represents peptideswith unique sequence
structure. The colour intensity of each cell corresponds to the peptide abundance (counts of sequences in log). Black represents peptides captured at higher abundance whereas white
represents peptides captured at lower abundance. D. Epitope mapping of anti-peptide response to human DP1 in sera of Pdmx-NT1 diseased. SPEXS2 analysis resulted in 2157 peptides
carrying RxxPxxxxD motif that were aligned to DP1 protein sequence (Q13258) with a 2-fold higher abundance over random as a chosen criterion. In addition, MEME-MAST algorithm
(Bailey and Elkan, 1994) aligned these 2157peptides to the regionencompassing94-101aaofDP1, E-value=0.0078. Each bar on thex-axis corresponds to oneof the overlapping peptides
required to cover the antigen, and the height of the proﬁles shows the relative abundance. Three potentially immunogenic regions were described with the predominant alignment con-
taining the sequence RVLAPALD and encompassing amino acids 94 to 101. Zoomed in the box is an extract of the immunoproﬁle of DP1 in positions 90–106. Calculated relative abundance
values are marked above each amino acid position. Note that the weaker immunogenic regions of DP1 are expanded toward both N- and C-termini. Abbreviations: Abundance – peptide
frequency; Divergence – all unique peptides; HC- healthy control;H1N1-HC – H1N1 infected; Pdmx-HC- Pandemrix-vaccinated; NT1- narcolepsy type 1 (including 10 Pandemrix-induced
NT1 samples).
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OX neurons are yet unknown.
Here we show that the DP1 receptor is linked to NT1 by acting as a
possible antigen in the disease process. Prostaglandins play a key role
in the inﬂammatory response and their synthesis is signiﬁcantlyincreased after tissue injury and cell stress (Ricciotti and Fitzgerald,
2011). PGD2 is a major eicosanoid both in the Central Nervous System
(CNS) and peripheral tissues with a role in inﬂammation as well as ho-
meostasis (Jowsey et al., 2001; Vijay et al., 2017). PGD2 is abundantly
produced by mast cells and Th2 cells, and among a wide range of
Fig. 5.Validation of DP1 as a true antigenic target in NT1 disease. A. HumanDP1 is expressedwidely in different brain regions, and bymesenchymal and cancer stem cells. Cerebral cortex:
Frontal cerebral cortex, Occipital lobe, Frontal lobe, Parietal lobe, Hippocampus; brain nuclei: Tectum, Amygdala, Thalamus, Caudate nucleus, Substantia nigra, Putamen, Nucleus ruber, Globus
pallidus; Cerebellum: Cerebellar nuclei, Cerebellum right, Cerebellum left; Brainstem: Ventral pons, Dorsal pons, Dorsal medulla, Ventral medulla; Axonal tracts: Infundibulum, Optical nerve,
Dorsal caudal pedunculi, Pedunculi, Cerebellum white matter, Corpus callosum; human glioma cells (hGC_1, hGC_2); human mesenchymal stem cells (hMSC); NC – negative control. PCR
analyses were done using speciﬁc primers for human DP1. GAPDH mRNA expression was used to normalize the data across samples. B. PGD2/DP1 signaling is associated with
inﬂammation regulation. Expressions of human DP1, IL-1β,MMP1, IFNγ and IDO-1were analyzed by PCR in human mesenhymal stem cells treated with PGD2 (10 μM) or cytokines IL-
1β (1 ng/mL) and IFNγ (2 ng/mL). NC – negative control. GAPDH mRNA expression was used to normalize the data across samples. C. RVLAPALD was identiﬁed as a target antigen
sequence for NT1-speciﬁc polyclonal IgG response. Western blot analysis of phage particles containing the RVLAPALD-pIII (phage 1) or FLAG-pIII fusion proteins (phage 2) show that
human Pdmx-NT1 serum (dilution 1:500) reacted speciﬁcally with the pIII protein containing the peptide RVLAPALDSWGT sequence, but not with the phage backbone or FLAG-pIII
fusion protein. Duplicate membranes were incubated with Pdmx-NT1 sera treated with the synthetic peptide (RVLAPALDSWGTGGGDYKDDD: ﬁnal conc 6.6 μg/mL) that signiﬁcantly
blocked the interaction between phage #1 and human IgG similarly to anti-FLAG antibody (dilution 1:2000) and phage #2. RVLAPALDSWGT-pIII fusion protein was not detected by
HC sera (1: 500). Protein size markers are indicated at the right side of blot. D. NT1-speciﬁc seroreactivity to DP1 protein is speciﬁcally blocked by RVLAPALD peptide. Western blot
analysis of endogenous levels of DP1 protein (MW 40 kDa) in human glioma hGC_1 and hGC_2 cells using anti-PTGDR1 (DP1) polyclonal antibodies (1:500) (left, ﬁrst panels). Note
that, hGC_2 cells were negative of DP1 expression. The use of the Pdmx-NT1 serum (1:500) showed similar pattern of DP1 reactivity in hGC_1 and hGC_2 cells, and the DP1-speciﬁc
signal was attenuated by pre-treatments of Pdmx-NT1 sera with a synthetic peptide #1 (ﬁnal conc 6.6 μg/mL). Anti-GAPDH monoclonal antibody (1:10,000) was used as a control for
immunoblots. E. DP1 expressed by hMSCs and cancer was speciﬁcally blocked by RVLAPALD peptide. IF analysis of DP1 in hMSC and glioma cells. The antibodies used included: anti-
PTGDR1 (1:500; green), Pdmx-NT1 serum (1:400; red) and the secondary Alexa Flour 488 and 647 (Invitrogen, 1:2000) antibodies. For antibody-blocking, Pdmx-NT1 sera (1:400) and
synthetic peptide #1 (ﬁnal conc 6.6 μg/mL) were used. Cells were analyzed for phalloidin-labelled cytoskeleton proteins (green, left) and nuclear structures (Hoechst 33342, blue).
Abbreviations: Pdmx-NT1- Pandermix-induced narcolepsy type 1; HC – healthy control.
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stream effects by activating DP1 and DP2 receptors with opposing ef-
fects on cyclic AMP (cAMP) production, and/or phosphoinositol
turnover and intracellular Ca2+ mobilization (Liang et al., 2005). In
the brain, PGD2 regulates sleep, body temperature, and nociception
and its levels exhibit marked changes in different neuropathologies
(reviewed in (Liang et al., 2005, Mohri et al., 2006, Urade and
Hayaishi, 2011)). The microglial PGD2-DP1 pathway is also known to
mediate neuronal damage through microglial activation (Bate et al.,
2006; Vijay et al., 2017).
Among cells expressing DP1, mast cells (MCs) can release hista-
mine and other factors that affect sleep and the immune response
in the brain. Accumulating evidence shows that MCs play a role in
the regulation of sleep and behavior (Chikahisa et al., 2013). MCs
are most abundant in young individuals under the age of 19, after
which their counts decline with age (Porzionato et al., 2004;
Turygin et al., 2005).Most signiﬁcantly, the maturation of MCs is in-
ﬂuenced by PGD2 and the receptor DP1 (Taketomi et al., 2013). In
addition to histamine, DP1 signaling may also inﬂuence the levels
of adenosine that is known to regulate sleep (Urade and Hayaishi,
2011). The precise role of MCs and their released factors such as his-
tamine in NT1 warrants further studies.In conclusion, the present study shows that anti-DP1 antibodies are
autoimmuneagents in the course of NT1promptingmore studies on the
role of PDG2-DP1 signaling in OX-signaling and in the disease. Currently
DP1-selective agonist/antagonist therapies are considered in treating
autoimmune disorders such as asthma (Maicas et al., 2012; Santini
et al., 2016; Santus and Radovanovic, 2016). Our data also indicate
that, depending on the antibody concentrations and afﬁnities, anti-
DP1 antibodies may modify the function of pharmaceutical compounds
targeting PGD2-DP1–signaling pathways (Narumiya and Fitzgerald,
2001) that need to be taken into account in clinical studies.
Supporting evidence that the humoral response in the CNS is de-
rived from different peripheral tissue antigens is provided by the
ﬁndings that sera from NT1 diseased can bind brain and muscle
structures (Ahmed et al., 2014; Smith et al., 2004). There is a plethora
of data that genetic or experimental alterations of the OX system are
associated with NT1, however, OXs are not restricted to the CNS and
together with their receptors OX1R and OX2R are widely expressed
in peripheral tissues (see ref. in (Voisin et al., 2003)). BCL6, another
NT1 antigen, is a master regulator required in mature B-cells during
germinal center (GC) reaction (Ref in Pei et al. (2017)). NRXN1-α has
been isolated from brain and heart tissues suggesting a role also in
heart development (Nagase et al., 1998). TRIB2 is present in many
Fig. 6.Use ofMVA-deﬁned peptides for immunodiagnostic applications of NT1. A. ELISPOT analysis of peptides containingH1N1/HA-speciﬁc sequence ESTRYQL (peptide_3) conﬁrmed the
power of the peptide to discriminate samples of natural H1N1 infection fromHC (ANOVA p b .001). In box plots - yellow circlesmark the single individuals of study cohorts; red dotsmark
themean values; linemarks themedian values; innerwhiskersmark conﬁdence intervals for themean; boxesmark theupper and lower quartiles; outerwhiskersmark themax and themin
values (excluding outliers). B. ELISPOT analysis of peptides containing RVLAPALD (epitope of DP1) and KAPSAS (epitope of BCL6) (peptide_1 and _2, respectively) resulted in correct
assignment of 10 Pdmx-NT1 samples and 6 sNT1 samples to NT1 group (ANOVA p b .001). On box plots - blue circles mark the single individuals of study cohorts; red dots mark the
mean values; line marks the median values; inner whiskers mark conﬁdence intervals for the mean; boxes mark the upper and lower quartiles; outer whiskers mark the max and the
min values (excluding outliers). C. ELISPOT analysis data combined revealed the power of peptides 1, 2, and 3 to discriminate 11 (7 Pdmx-NT1 and 4 sNT1) out of 16 NT1 samples
across all samples (p b .001 Chi-squared test). Thresholds were calculated by using ROC curve analysis and results were visualised using scatter plot analysis with divided threshold
values (M1-M4). Statistical signiﬁcance of differences was calculated by two-way classiﬁcation Chi-square test (Chi-squared p-value N .001). Abbreviations: HC– healthy control; H1N1-
HC – H1N1 infected; Pdmx-HC- Pandemrix-vaccinated; NT1- narcolepsy type 1 (including 10 Pandemrix-induced NT1 samples).
56 H. Sadam et al. / EBioMedicine 29 (2018) 47–59cell populations both in and outside the nervous system, including
the immune cells (Eder et al., 2008; Sung et al., 2006). Gangliosides
(anti-GM3) are abundant in the brain, but in extraneural tissues, rel-
atively high concentrations of ganglio-series GMs were found in
bone marrow, erythrocytes, intestine, liver, spleen, testis, kidney,
and in embryonic stem cells (Kolter, 2012). NEI-MCH has mostly
been detected in peripheral organs (Viale et al., 1997). NT5C1A is
highly abundant in skeletal muscle tissue (Hunsucker et al., 2001).
GLS2 is expressed speciﬁcally in the liver, but also in extrahepatic tis-
sues, like the brain, pancreas, cells of the immune system (ref in
Martin-Ruﬁan et al. (2012)). However, it remains elusive what path-
ogenic roles these antibodies against the above-mentioned proteins
may exert within the periphery.
Our data of immunoproﬁling support the existence of immune de-
fects in multiple pathways associating NT1 to a) DP1 and PDG2/hista-
mine associated disorders, b) BCL6 and the chronic status of latent
herpesviruses (such as EBV), c) orexin/OX1/2R–related dysfunctions,
d) stress and inﬂammation-associated mitogen-activated pathways
(such as MAP3K7, also known as transforming growth factor (TGF)-β-
activated kinase 1 (TAK1)), and e) adenosine-deﬁciency linked dysfunc-
tions (involving NT5C1A) (Table S1, Fig. 7). Together these results pro-
vide a comprehensive map of potential molecular targets contributing
to NT1 that can be of help in designing future strategies for the diagnos-
tics and treatment of the disease. More broadly, our study demonstratesthe usefulness of MVA as a method for disease classiﬁcation and for the
discovery of novel biomarkers that can be applicable to any human
disease.
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Fig. 7. Hypothetical model for the aggravation of autoimmune response in Pdmx-associated and spontaneous NT1. The immune response in NT1 is highly heterogenic with different
pathways affected during the disease progression. We favor the idea that the lifelong risk for NT1 or for disease aggravation in pre-disposed individuals is increased following
inﬂammatory triggers upon breaching of the blood–brain barrier (BBB) and with activation of preexisting auto-reactive antibodies (Ab) and cells reaching brain. Consequently, an
immune response to A/H1N1 (and subsequent molecular mimicry) or a generalized stimulation of the immune system mediated by the Pdmx vaccine as AS03-adjuvanted vaccine can
act as the inﬂammatory trigger (Morel et al., 2011; Carmona et al., 2010; Meyer et al., 2011). The inﬂammation triggers include i) infections (examples of pathogens are shown), ii)
genetic factors, or iii) chronic inﬂammation (Kornum et al., 2011). The polyclonal Ab response from peripheral tissue may initiate disease by concentrating antigens in the brain to
presentation-competent cells (Getahun et al., 2004). Recent data show further that peripherally produced human anti-CNS reactive antibodies are capable of opsonizing human CNS
antigens (Kinzel et al., 2016). The entry of immune cells (T cells, B cells, macrophages, microglia and mast cells) cause neuroinﬂammation with the release of cytokines that damage
neurons including HCRT+ neurons involved in sleep/wake regulation. Production of auto-reactive antibodies as a secondary response to cell death of HCRT-or other brain-resident
cells can occur via antigen presenting cells. Prostaglandins are part of the inﬂammatory response in the brain acting via speciﬁc receptors. In particular, DP1 is produced by astrocytes,
oligodendrocytes, neurons, microglia and meningeal cells (Liang et al., 2005; Mohri et al., 2007; Beuckmann et al., 2000). PGD2 signaling is known to prevent excessive inﬂammasome
activation and may act as an anti-inﬂammatory pathway in the brain. Additionally, in brain residing mast cells, DP1 activity promotes maturation and histamine release (Taketomi
et al., 2013). The latter is of particular interest given that histamine levels in the CSF of NT1-diseased are reduced (Nishino et al., 2009). Thus, our ﬁndings suggest that the anti-DP1
immune response, whether causal or sequel, can interfere with PGD2 signaling in the brain. The results provide also evidence that the dysfunctional DP1 network can be a target for
diagnosis and intervention of NT1, a conclusion that warrants further investigations.
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